COMMUNIQUÉS West-GlobeNewswire

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
27/04/2026
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free [...]
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
27/04/2026
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to [...]
Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it intends to utilize up [...]
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
27/04/2026
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation
27/04/2026
Recognition honors the ground-up rebuild of NIMA’s gluten sensor, app, and quality systems BOSTON, April 27, 2026 (GLOBE NEWSWIRE) -- NIMA Partners, Inc . announced today it has been named the winner of a Gold Stevie® [...]
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
27/04/2026
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations and drug-drug [...]
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
27/04/2026
– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing [...]
Suja Life Announces Launch of Initial Public Offering
27/04/2026
OCEANSIDE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Suja Life, Inc. (“Suja Life”) today announced that it has commenced the roadshow for its proposed initial public offering. Suja Life has filed a registration [...]
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
27/04/2026
SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
27/04/2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) [...]
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
27/04/2026
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton [...]
Sagimet Biosciences Provides Strategic and Corporate Updates
27/04/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH [...]
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
27/04/2026
Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of Stockholders REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the [...]
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
27/04/2026
Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across [...]
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of [...]
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
27/04/2026
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6- [...]
Composition of the Nomination Committee of Orion Corporation
27/04/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 APRIL 2026 at 12:00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]
KFSH Highlights Scalable AI Integration Model at C3 Davos of Healthcare™ Silicon Valley Summit
27/04/2026
SUNNYVALE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- As global health systems shift from isolated digital initiatives to integrated, data-driven care models, King Faisal Specialist Hospital & Research Centre (KFSH [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]

Pages